OICHARTS
8 AMThe 8 AM report →

BIOCON

Biocon Limited · NSE · INE376G01013 · F&O · lot 2,500 · 272 sessions on record
₹370.70▲ +0.40 · +0.1%from ₹370.30 the session before · 1 Oct 2026 close · NSE end of day
Open
₹370.55
High
₹374.25
Low
₹363.60
Day's range
₹112.9% of the previous close
VWAP
₹369.52close +0.32% from it
Volume, shares
25 L0.78× the 20-session average
Turnover, ₹ crore
93
Trades
43,00058 shares per trade
Previous close
₹370.30+0.40 to the close
Price band, next session
₹333.65 – ₹407.7510% either side of the close · dynamic, widened in 5% steps when hit
Day range67% of the way up
₹363.60₹374.25
52-week range30% of the way up
₹337.70 7 Apr₹447.15 16 Jul

−17% from the high · +9.8% from the low

The desk read · 1 Octexpiry 27 Oct · 26 days
short covering
futures read
price +0.1% · OI −1.1%
+2.40
futures premium, ₹
+0.7% to spot ₹370.70
0.83
puts per call, by OI
by volume 0.56
380
max pain
+2.5% from the close
▼ −1.1%
futures OI on the day
−230 lots · 22,000 open

Short covering into a 26-day expiry: futures OI −1.1% on a +0.1% day, the most call OI sits at 400, the most put OI at 360, max pain 380.

Futures and options

1 Oct close · lot 2,500 · NSE end of day

BIOCON futures closed at ₹373.10, +0.7% to spot, with 98% of open interest in the 27 Oct contract, and the 370 straddle prices a move of about ±5.4% by expiry.

Futures by expiryall 3 contracts NSE lists on the stock · basis against the spot close ₹370.70
Futures by expiry, basis against the spot close ₹370.70
ExpiryClose ₹Basis ₹ · %Annualised %OI lots · on the dayShare of OI %Contracts traded
27 Oct26 days₹373.10+2.40+0.7%+9.1%21,000▼ −1.2% · −260 lots982,000
23 Nov53 days₹375.30+4.60+1.2%+8.6%430▲ +3.4% · +14 lots2.064
29 Dec89 days₹376.50+5.80+1.6%+6.4%12▲ +1100.0% · +11 lots0.0617

2.0% of futures OI sits beyond the 27 Oct contract · 38 of 58 listed contracts traded · 7,800 option contracts changed hands

Options27 Oct expiry · 26 days

The 370 straddle closed at ₹20.05 (call 11.55 + put 8.50), pricing a move of about ±5.4% by the 27 Oct expiry. In the last 253 windows of 19 sessions, BIOCON moved more than that 106 times.

Call OI, lots
5,9001.5 cr shares
Put OI, lots
4,9001.2 cr shares
Puts per call, by OI
0.83by volume 0.56
Max pain
380+2.5% from the close
Contracts traded
38 of 58listed for this expiry
Open interest by strike, lotstop three strikes each side
Calls
Strike
Puts
2,000
400
430
390
1,200
380
650
365
370
360
1,500
Open interest added on the day, lotsthree largest additions each side
Calls
Strike
Puts
+150
400
+140
380
+130
+170
370
+100
365
+49
Close ₹ · Nifty 50 rebased to the first close · futures open interest by the day's build-up126 sessions to 1 Oct · axis fixed at 4 × ATR-14 around the last close
272 sessions on file · from 28 Aug
BIOCON close and futures open interest over the last 126 sessions, with Nifty 50 rebased to the first close332.15386.42440.70axis spans 33%Nifty 50BIOCON1 Apr6 Jul1 OctFutures open interest, lotspeak 24,000126 sessions from 1 Apr to 1 Oct; the price axis spans 33 percent.

The market after the news

close against the last close before each bulletin · Nifty 50 over the same sessions

After the last 8 bulletins, BIOCON closed higher five sessions later in 4 of 8.

Close after each bulletin on the day, one session later and five sessions later, with Nifty 50 and futures open interest
BulletinDay of the news1 session later5 sessions laterFutures OI on the day
18 JulBiocon shares rise 6% on ₹3,680 cr block deal▼ −0.2%Nifty −0.4% · +0.2 pp▲ +0.7%Nifty −0.6% · +1.3 pp▼ −0.2%Nifty −1.4% · +1.2 pp▼ −1.3%long unwinding
17 JulBiocon shares rise 6% after ₹3,680 cr block deal▼ −0.2%Nifty −0.4% · +0.2 pp▲ +0.7%Nifty −0.6% · +1.3 pp▼ −0.2%Nifty −1.4% · +1.2 pp▼ −1.3%long unwinding
17 JulBiocon secures EMA approval for Semglee production line▼ −0.8%Nifty +1.1% · −1.9 pp▼ −0.9%Nifty +0.7% · −1.6 pp▼ −1.6%Nifty −1.3% · −0.3 pp▼ −5.7%long unwinding
16 JulBiocon secures EMA approval for Semglee production line▼ −0.8%Nifty +1.1% · −1.9 pp▼ −0.9%Nifty +0.7% · −1.6 pp▼ −1.6%Nifty −1.3% · −0.3 pp▼ −5.7%long unwinding
16 JulMylan exits Biocon with ₹3,679 crore block deal▲ +1.4%Nifty 0.0% · +1.4 pp▲ +0.6%Nifty +1.1% · −0.5 pp▲ +0.1%Nifty −0.9% · +1.0 pp▲ +1.2%long build-up
15 JulMylan exits Biocon with ₹3,679 crore block deal▲ +1.4%Nifty 0.0% · +1.4 pp▲ +0.6%Nifty +1.1% · −0.5 pp▲ +0.1%Nifty −0.9% · +1.0 pp▲ +1.2%long build-up
15 JulBiocon shares rise 8% on Mylan's ₹3,481 crore block deal▼ −0.6%Nifty +0.1% · −0.7 pp▲ +0.8%Nifty +0.1% · +0.7 pp▲ +0.1%Nifty −0.2% · +0.4 pp▼ −0.8%long unwinding
14 JulBiocon shares rise 8% on Mylan's ₹3,481 crore block deal▼ −0.6%Nifty +0.1% · −0.7 pp▲ +0.8%Nifty +0.1% · +0.7 pp▲ +0.1%Nifty −0.2% · +0.4 pp▼ −0.8%long unwinding
8 of 24 bulletins

Quarterly results

consolidated · latest filed 5 Aug, 05:21 pm IST · NSE filings

Revenue ₹4,336 cr, +10% on a year earlier; profit ₹137 cr, +53% in the Jun 2026 quarter, consolidated.

Last 8 quarters, consolidated₹ crore as filed · year on year against the same quarter a year earlier · market: close on the first session after the filing against the last close before it, Nifty 50 over the same session
Quarterly results of BIOCON on the consolidated basis with the market's move on the first session after each filing
QuarterRevenue ₹ crRevenue YoYProfit ₹ crProfit YoYEPS ₹Market on the day
Jun 2026filed 5 Aug₹4,336 cr▲ +10%₹137 cr▲ +53%0.87▲ +2.7%Nifty +0.1% · +2.6 pp
Mar 2026filed 8 May · audited₹4,517 cr▲ +2.3%₹199 cr▼ −57%0.79▼ −0.5%Nifty −0.6% · +0.1 pp
Dec 2025filed 12 Feb₹4,173 cr▲ +9.2%−₹52 cr▼ −160%1.07▲ +0.8%Nifty −1.3% · +2.1 pp
Sept 2025filed 11 Nov₹4,296 cr▲ +20%₹133 cr▲ +390%0.65▲ +5.4%Nifty +0.7% · +4.7 pp
Jun 2025filed 7 Aug₹3,942 cr▲ +15%₹89 cr▼ −90%0.26▼ −5.7%Nifty −0.9% · −4.8 pp
Mar 2025filed 8 May · audited₹4,417 cr▲ +13%₹459 cr▲ +110%2.87▼ −1.4%Nifty −1.1% · −0.3 pp
Dec 2024filed 31 Jan₹3,821 cr▼ −3.3%₹81 cr▼ −89%0.21▲ +1.6%Nifty +1.1% · +0.4 pp
Sept 2024filed 30 Oct₹3,590 cr▲ +3.7%₹27 cr▼ −84%-0.13▼ −1.4%Nifty −0.6% · −0.9 pp
By financial yearApril to March · each year the sum of its four quarters as filed, consolidated · EPS summed across the quarters · only complete years
Financial-year results of BIOCON on the consolidated basis, summed from the quarters filed
YearRevenue ₹ crRevenue YoYProfit ₹ crProfit YoYEPS ₹
FY26to Mar 2026₹16,927 cr▲ +11%₹369 cr▼ −74%2.77
FY25to Mar 2025₹15,262 cr▲ +3.4%₹1,429 cr▲ +10%8.46
FY24to Mar 2024₹14,756 cr—₹1,298 cr—8.54

Fundamentals

consolidated · filings to Jun 2026 · close ₹370.70 on 1 Oct

BIOCON trades at 110 times trailing earnings against 38 for its industry, 1.6 times book value, revenue +9.8% over twelve months, a 0.27% dividend yield, market cap ₹60,000 cr.

Valuationarithmetic on filings and the close · each cell names what it rests on · — where an input is missing
Market cap
₹60,000 cron 1 Oct · free float ₹33,000 cr
Price to earnings
110consolidated · four quarters to Jun 2026 · industry 38
Trailing EPS
₹3.38diluted · consolidated · four quarters to Jun 2026
Price to book
1.6consolidated · balance sheet to Mar 2026
Book value a share
₹224.71consolidated · balance sheet to Mar 2026 · over NSE's share count
Debt to equity
0.40borrowings over equity · consolidated · balance sheet to Mar 2026
Return on equity
1.3%trailing profit over average equity · consolidated
Dividend yield
0.27%₹1.00 a share in 365 days
Face value
₹5a share
Shares outstanding
163 cron 1 Oct
Growthsums of the four quarters filed to Jun 2026 · growth against the four quarters before them · consolidated
Revenue, trailing 12 months
₹17,321 crfour quarters to Jun 2026
Revenue growth, 12 months
▲ +9.8%against the twelve months before
Revenue 3-year CAGR
▲ +12%trailing twelve months against the twelve months 3 years earlier · consolidated
Profit, trailing 12 months
₹416 crfour quarters to Jun 2026
Profit growth, 12 months
▼ −37%against the twelve months before
Profit 3-year CAGR
▼ −13%trailing twelve months against the twelve months 3 years earlier · consolidated
PeersBSE sub-group Pharmaceuticals · F&O stocks with filings on record · industry P/E 38, market caps over trailing profit of 13 stocks
Stocks in the BSE sub-group Pharmaceuticals with market cap, price to earnings and price to book
StockMarket cap ₹P/EP/BClose ₹
SUNPHARMASun Pharmaceutical Industries Limited4,30,000 cron 1 Oct36consolidated5.2₹1,801.00
DIVISLABDivi's Laboratories Limited2,50,000 cron 1 Oct52consolidated15₹9,249.00
TORNTPHARMTorrent Pharmaceuticals Limited1,80,000 cron 1 Oct76consolidated10₹4,767.30
ZYDUSLIFEZydus Lifesciences Limited1,10,000 cron 1 Oct26consolidated3.9₹1,145.70
CIPLACipla Limited1,10,000 cron 1 Oct32consolidated3.1₹1,344.00
LAURUSLABSLaurus Labs Limited1,10,000 cron 1 Oct85consolidated20₹1,984.00
MANKINDMankind Pharma Limited1,00,000 cron 1 Oct51consolidated6.3₹2,535.00
DRREDDYDr. Reddy's Laboratories Limited1,00,000 cron 1 Oct31consolidated2.6₹1,206.20
AUROPHARMAAurobindo Pharma Limited96,000 cron 1 Oct26consolidated2.5₹1,676.80
LUPINLupin Limited93,000 cron 1 Oct17consolidated4.1₹2,031.20
GLENMARKGlenmark Pharmaceuticals Limited66,000 cron 1 Oct37consolidated6.3₹2,331.00
ALKEMAlkem Laboratories Limited62,000 cron 1 Oct29consolidated4.3₹5,220.00
BIOCONBiocon Limited60,000 cron 1 Oct110consolidated1.6₹370.70
ABBOTINDIAAbbott India Limited57,000 cron 1 Oct——₹26,840.00
IPCALABIPCA Laboratories Limited49,000 cron 1 Oct—5.2₹1,943.20
GLANDGland Pharma Limited47,000 cron 1 Oct—4.6₹2,874.40
GLAXOGlaxoSmithKline Pharmaceuticals Limited47,000 cron 1 Oct—21₹2,771.10
AJANTPHARMAjanta Pharma Limited45,000 cron 1 Oct—9.9₹3,581.00
EMCUREEmcure Pharmaceuticals Limited37,000 cron 1 Oct—7.4₹1,944.60
WOCKPHARMAWockhardt Limited34,000 cron 1 Oct—6.4₹2,083.90
SAILIFESai Life Sciences Limited33,000 cron 1 Oct—13₹1,541.20
NEULANDLABNeuland Laboratories Limited28,000 cron 1 Oct—15₹21,505.00
RUBICONRubicon Research Limited27,000 cron 1 Oct—21₹1,630.90
PPLPHARMAPiramal Pharma Limited26,000 cron 1 Oct—3.2₹197.95
ACUTAASAcutaas Chemicals Limited26,000 cron 1 Oct—15₹3,196.50
SHILPAMEDShilpa Medicare Limited21,000 cron 1 Oct—8.0₹1,064.10
GRANULESGranules India Limited20,000 cron 1 Oct—4.0₹821.75
CAPLIPOINTCaplin Point Laboratories Limited20,000 cron 1 Oct—5.5₹2,631.90
PFIZERPfizer Limited18,000 cron 1 Oct—4.2₹3,858.90
ONESOURCEOnesource Specialty Pharma Limited17,000 cron 1 Oct—3.0₹1,508.00
COHANCECohance Lifesciences Limited17,000 cron 1 Oct—4.3₹451.30
ALIVUSAlivus Life Sciences Limited17,000 cron 1 Oct—5.1₹1,374.20
ERISEris Lifesciences Limited16,000 cron 1 Oct—4.2₹1,189.80
NATCOPHARMNatco Pharma Limited16,000 cron 1 Oct—1.8₹821.30
APLLTDAlembic Pharmaceuticals Limited16,000 cron 1 Oct—2.8₹815.25
JUBLPHARMAJubilant Pharmova Limited16,000 cron 1 Oct—2.2₹999.30
ASTRAZENAstraZeneca Pharma India Limited15,000 cron 1 Oct—17₹6,031.00
MARKSANSMarksans Pharma Limited15,000 cron 1 Oct—4.8₹325.60
CONCORDBIOConcord Biotech Limited14,000 cron 1 Oct—7.1₹1,374.10
AKUMSAkums Drugs and Pharmaceuticals Limited13,000 cron 1 Oct—3.8₹813.10
CORONACORONA Remedies Limited12,000 cron 1 Oct—17₹2,029.40
BLUEJETBlue Jet Healthcare Limited10,000 cron 1 Oct—7.5₹541.80
VIYASHViyash Scientific Limited10,000 cron 1 Oct—3.3₹231.75
STARStrides Pharma Science Limited10,000 cron 1 Oct—3.2₹1,084.80
PGHLProcter & Gamble Health Limited8,900 cron 1 Oct—17₹5,360.00
AARTIPHARMAarti Pharmalabs Limited8,800 cron 1 Oct—4.1₹968.50
SANOFICONRSanofi Consumer Healthcare India Limited8,700 cron 1 Oct—25₹3,787.20
SYMBIOTECSymbiotec Pharmalab Limited7,700 cron 1 Oct——₹1,198.00
SUPRIYASupriya Lifescience Limited7,500 cron 1 Oct—6.3₹931.00
MOREPENLABMorepen Laboratories Limited7,300 cron 1 Oct—5.9₹133.70
SANOFISanofi India Limited7,000 cron 1 Oct—8.5₹3,037.40
INNOVACAPInnova Captab Limited6,700 cron 1 Oct—6.1₹1,168.00
SPARCSun Pharma Advanced Research Company Limited6,300 cron 1 Oct—4.7₹194.15
SENORESSenores Pharmaceuticals Limited6,200 cron 1 Oct—6.4₹1,349.60
IOLCPIOL Chemicals and Pharmaceuticals Limited6,100 cron 1 Oct—3.4₹209.40
ORCHPHARMAOrchid Pharma Limited5,900 cron 1 Oct—4.6₹990.00
FDCFDC Limited5,500 cron 1 Oct—2.2₹335.90
GUJTHEMGujarat Themis Biosyn Limited5,000 cron 1 Oct——₹381.80
NOVARTINDNovartis India Limited4,900 cron 1 Oct——₹1,965.00
RPGLIFERPG Life Sciences Limited4,800 cron 1 Oct—8.0₹2,930.70
SMSPHARMASMS Pharmaceuticals Limited4,400 cron 1 Oct—5.6₹471.30
GUFICBIOGufic Biosciences Limited4,200 cron 1 Oct—6.3₹418.40
AARTIDRUGSAarti Drugs Limited3,800 cron 1 Oct—2.5₹421.00
UNICHEMLABUnichem Laboratories Limited3,800 cron 1 Oct—1.4₹535.05
KPLKwality Pharmaceuticals Limited3,700 cron 1 Oct——₹3,564.40
SOLARASolara Active Pharma Sciences Limited3,400 cron 1 Oct—2.7₹714.85
INDSWFTLABInd-Swift Laboratories Limited3,400 cron 1 Oct—2.5₹395.15
SHUKRAPHARShukra Pharmaceuticals Limited2,700 cron 1 Oct——₹61.80
HIKALHikal Limited2,700 cron 1 Oct—2.2₹218.15
VENUSREMVenus Remedies Limited2,400 cron 1 Oct—3.6₹1,796.70
DCALDishman Carbogen Amcis Limited2,400 cron 1 Oct—0.35₹150.35
INDOCOIndoco Remedies Limited2,300 cron 1 Oct—2.5₹251.75
SAIPARENTSai Parenterals Limited2,300 cron 1 Oct—4.7₹523.65
SYNCOMFSyncom Formulations (India) Limited2,300 cron 1 Oct—5.4₹23.95
FREDUNFredun Pharmaceuticals Limited2,200 cron 1 Oct——₹1,355.20
WINDLASWindlas Biotech Limited2,200 cron 1 Oct——₹1,082.40
PANACEABIOPanacea Biotec Limited2,200 cron 1 Oct—2.6₹359.05
HESTERBIOHester Biosciences Limited1,800 cron 1 Oct—4.9₹2,126.80
NGLFINENGL Fine-Chem Limited1,800 cron 1 Oct—5.5₹2,924.00
AHCLAnlon Healthcare Limited1,700 cron 1 Oct—6.8₹32.85
FERMENTAFermenta Biotech Limited1,600 cron 1 Oct——₹553.25
JAGSNPHARMJagsonpal Pharmaceuticals Limited1,500 cron 1 Oct—5.5₹231.75
AMRUTANJANAmrutanjan Health Care Limited1,500 cron 1 Oct—4.0₹513.20
KOPRANKopran Limited1,400 cron 1 Oct—2.6₹282.05
BPLPHARMABharat Parenterals Limited1,200 cron 1 Oct——₹1,720.40
LINCOLNLincoln Pharmaceuticals Limited1,200 cron 1 Oct—1.5₹582.05
BAJAJHCAREBajaj Healthcare Limited1,100 cron 1 Oct—2.0₹322.95
SIGACHISigachi Industries Limited1,100 cron 1 Oct—2.0₹28.35
THEMISMEDThemis Medicare Limited1,000 cron 1 Oct—2.6₹113.20
SGRLShree Ganesh Remedies Limited890 cron 1 Oct——₹694.25
ANUHPHRAnuh Pharma Limited860 cron 1 Oct—2.4₹85.85
ZIMLABZim Laboratories Limited740 cron 1 Oct—2.5₹137.00
WANBURYWanbury Limited690 cron 1 Oct—4.8₹198.00
ALBERTDAVDAlbert David Limited490 cron 1 Oct—1.3₹856.70
MEDICAMEQMedicamen Biotech Limited470 cron 17 Sept—1.7₹346.30
HALEOSLABSHALEOS LABS LIMITED450 cron 1 Oct—2.0₹1,490.00
JENBURPHJenburkt Pharmaceuticals Limited400 cron 1 Oct——₹915.25
AAREYDRUGSAarey Drugs & Pharmaceuticals Limited290 cron 1 Oct—2.0₹103.85
NECLIFENectar Lifesciences Limited200 cron 1 Oct—0.34₹10.25
MEDICOMedico Remedies Limited180 cron 1 Oct—2.4₹21.85
BALPHARMABal Pharma Limited170 cron 1 Oct—2.0₹105.75
BROOKSBrooks Laboratories Limited160 cron 1 Oct—1.3₹54.80
KREBSBIOKrebs Biochemicals and Industries Limited150 cron 1 Oct——₹68.05
PARNAXLABParnax Lab Limited130 cron 1 Oct——₹113.15
ALPAAlpa Laboratories Limited120 cron 1 Oct—0.67₹59.25
MAKERSLMakers Laboratories Limited110 cron 1 Oct——₹183.50
SUNLOCSunil Healthcare Limited72 cron 1 Oct——₹70.10
VINEETLABVineet Laboratories Limited69 cron 1 Oct—1.5₹35.90
BIOFILCHEMBiofil Chemicals & Pharmaceuticals Limited48 cron 1 Oct—2.2₹29.30
MANGALAMMangalam Drugs And Organics Limited46 cron 1 Oct—0.45₹29.15
MEDICAPQMedi Caps Limited31 cron 17 Sept——₹24.80
ORTINGLOBEORTIN GLOBAL LIMITED12 cron 1 Oct—9.5₹14.50
AMANTAAmanta Healthcare Limited————
AMBALALSAAmbalal Sarabhai Enterprises Limited————
BAFNAPHBafna Pharmaceuticals Limited————
BLISSGVSBliss GVS Pharma Limited————
KILITCHKilitch Drugs (India) Limited————
LASALasa Supergenerics Limited————
LYKALABSLyka Labs Limited————
NATCAPSUQNatural Capsules Limited————
VALIANTLABValiant Laboratories Limited————
VIVIMEDLABVivimed Labs Limited————

Shareholding

quarter to 30 Jun · none pledged · NSE filings

Promoters hold 44.7%, foreign portfolio investors 8.1%, mutual funds 15.5% and insurance companies 6.4%, as filed for the quarter to 30 Jun.

By category, last 5 quarterspercent of shares · beneath each figure, the change in percentage points against the previous quarter on file
Shareholding of BIOCON by category over the last 5 quarters with the change against the previous quarter
Category30 Jun29 Jun31 Mar14 Jan5 Jan
Promoters44.680.00 pp44.68▼ −0.23 pp44.910.00 pp44.91▼ −3.36 pp48.27
Foreign portfolio investors8.14▼ −0.02 pp8.16▲ +0.64 pp7.52▲ +0.38 pp7.14▲ +0.58 pp6.56
Mutual funds15.47▼ −0.02 pp15.49▼ −1.04 pp16.53▼ −0.50 pp17.03▲ +4.86 pp12.17
Insurance companies6.37▲ +0.04 pp6.33▲ +0.17 pp6.160.00 pp6.16▲ +0.04 pp6.12
Banks and financial institutions1.540.00 pp1.54▲ +0.17 pp1.37▲ +0.40 pp0.97▼ −0.39 pp1.36
Individual investors11.05▲ +0.02 pp11.03▲ +0.27 pp10.76▼ −0.23 pp10.99▼ −0.79 pp11.78
Bodies corporate6.15▼ −0.02 pp6.170.00 pp6.17▲ +0.30 pp5.87▼ −0.43 pp6.30
Other foreign holders5.640.00 pp5.64▼ −0.03 pp5.670.00 pp5.67▼ −0.43 pp6.10
Others0.960.00 pp0.96▲ +0.05 pp0.91▼ −0.35 pp1.26▼ −0.08 pp1.34

Corporate actions

NSE and BSE records

Nothing upcoming on record; the last was a dividend of ₹0.50 a share, ex-date 3 Jul 2026.

Actionsex-dates · upcoming first, then the last eight · dividends in rupees a share, bonus and split as ratios
Corporate actions of BIOCON, upcoming first, then the most recent
Ex-dateActionAmount or ratioRecord dateSource
recent
3 Jul 2026dividend₹0.503 Jul 2026BSE
4 Jul 2025dividend₹0.504 Jul 2025BSE
5 Jul 2024dividend₹0.505 Jul 2024BSE
Calendaras notified to the exchange
Next results
—no board meeting notified yet
Dividends in 365 days
₹1.00a share · ex-dates inside the year
Last dividend
₹0.50ex-date 3 Jul 2026

Price history

272 sessions on record · to 1 Oct · NSE end of day

BIOCON is −7.6% over 20 sessions against Nifty's −6.2%, 17% below its 52-week high, realised volatility 22% annualised.

Returns against Nifty 50longest window first · Nifty 50 over the same sessions
Returns of the stock and Nifty 50 over six windows, longest first
WindowFrom ₹BIOCON %Nifty 50 %Difference pp
250 sessionssince 26 Sept₹338.91▲ +9.4%▼ −9.1%+18
120 sessionssince 9 Apr₹345.71▲ +7.2%▼ −5.7%+13
60 sessionssince 8 Jul₹397.07▼ −6.6%▼ −6.1%−0.53
20 sessionssince 2 Sept₹401.02▼ −7.6%▼ −6.2%−1.3
5 sessionssince 24 Sept₹386.99▼ −4.2%▼ −2.8%−1.4
1 sessionsince 30 Sept₹370.29▲ +0.11%▼ −0.88%+0.99
Averages of the closeclose against each average
5-session average
₹375.01close −1.1% from it
20-session average
₹386.19close −4.0% from it
50-session average
₹407.10close −8.9% from it
200-session average
₹394.94close −6.1% from it
Range and volumetrue range over 14 sessions · high to low over 20 · volume against the 20-session average
Average true range, 14
₹9.62.6% of the close
Average day's range, 20
₹8.82.4% of the close
Volume against 20 sessions
0.78×25 L vs 33 L average
Volatility and co-movement with Nifty 50annualised from daily log returns · counts share one denominator per cell
Realised volatility, 20
22%≈ ±1.4% a session · moved more than that on 8 of 20
Realised volatility, 60
25%≈ ±1.6% a session · moved more than that on 16 of 60
Realised volatility, 250
25%≈ ±1.6% a session · moved more than that on 64 of 250
Beta to Nifty, 60
0.60moved with Nifty on 35 of 60 sessions
Beta to Nifty, 250
0.66moved with Nifty on 153 of 250 sessions
Up and down sessionscloses above and below the previous close
Last 20 sessions
9 up · 11 downof 20
Last 60 sessions
26 up · 34 downof 60
Last 250 sessions
131 up · 118 downof 249
Best session, 250
▲ +6.4%14 Jul
Worst session, 250
▼ −5.3%4 Dec

Biocon Limited is in 17 NSE indices

all 17 indices

24 bulletins on BIOCON

latest 18 Jul 2026

Beats in the coverage

Often mentioned with

July 2026

Biocon shares rise 6% on ₹3,680 cr block dealBiocon shares surged over 6% after a ₹3,680 cr block deal saw 5.64% of its equity change hands. The shares traded at an average price of ₹400 each, alleviating supply concerns for the stock.High Biocon shares rise 6% after ₹3,680 cr block dealBiocon shares surged 6% after a ₹3,680 cr block deal saw 5.6% of its equity change hands. Approximately 9.2 crore shares were traded at ₹400 each, easing supply concerns for the stock.High Biocon secures EMA approval for Semglee production lineBiocon received EMA approval for its Semglee insulin production line in Malaysia, with shipments expected in FY27. Following the announcement, shares rose 0.6% to ₹437.2, while Mylan executed a ₹3,680 crore block deal involving 9.2 crore shares.Medium Biocon secures EMA approval for Semglee production lineBiocon secured EMA approval for its Semglee insulin production line in Malaysia, enabling shipments expected in FY27. Shares rose 0.6% to ₹437.2 following this news, while Mylan executed a ₹3,680 crore block deal involving Biocon shares.Medium Mylan exits Biocon with ₹3,679 crore block dealMylan Inc exited Biocon by selling its entire 5.64% stake for ₹3,679 crore through open market transactions. The sale involved 9,19,67,019 shares at an average price of ₹400 each, impacting Biocon's share price, which was down 0.47% at ₹435.25.High Mylan exits Biocon with ₹3,679 crore block dealMylan Inc exited Biocon by selling its entire 5.64% stake for ₹3,679 crore through open market transactions. Biocon shares traded lower at ₹435.25, reflecting market reaction to the significant stake sale.High Biocon shares rise 8% on Mylan's ₹3,481 crore block dealBiocon shares surged 8% as Mylan launched a ₹3,481 crore block deal to sell its entire stake in the biopharmaceutical company, marking a significant exit. The deal involves 9.2 crore shares at a floor price of ₹378.50 each.High Biocon shares rise 8% on Mylan's ₹3,481 crore block dealBiocon shares jumped 8% as Mylan launched a block deal to sell its entire stake, valued at ₹3,481 crore. The transaction involves 9.2 crore shares at a floor price of ₹378.50, marking Mylan's complete exit from the company.High

June 2026

Biocon secures $54m insulin tender in MalaysiaBiocon, alongside Duopharma Biotech, secured three insulin contracts from Malaysia’s Ministry of Health worth $54 million. This deal enhances Biocon's market presence and may positively impact its revenue growth in the Pharma sector.High Biocon secures $54m insulin tender in MalaysiaBiocon, alongside Duopharma Biotech, secured three insulin contracts from Malaysia’s Ministry of Health totaling $54 million. This deal enhances Biocon's market presence and could positively impact its revenue in the region.High Biocon partner secures ₹500 cr insulin supply contractDuopharma Biotech, a partner of Biocon, secured a ₹515 cr insulin supply contract from the Malaysian Ministry of Health. The agreement includes a three-year supply of human insulin worth ₹350 cr and additional contracts for insulin glargine and aspart.High

May 2026

Biocon Q4 net profit declines 57% to ₹198.6 croreBiocon Ltd reported a 56.8% decline in Q4 net profit to ₹198.6 crore, impacted by an exceptional item outgo. Revenue rose to ₹4,516.6 crore, while total expenses increased to ₹4,241.2 crore. A final dividend of 50 paise per share is proposed, subject to approval.Medium Indian firms commit $20.5 billion to US investmentsIndian firms pledged $20.5 billion in the US, with the pharmaceutical sector leading at $19.1 billion. Sun Pharmaceutical's $11.75 billion acquisition of Organon & Co. highlights the sector's growth potential and may boost market sentiment.High Biocon shares dip 1% after FDA inspection issuesBiocon's stock dropped 1% after the FDA raised five issues at its Bengaluru facility during an inspection on April 30, 2026. The company claims these are procedural and poses no risk to data integrity, while also securing Health Canada approvals for two denosumab biosimilars.Medium

April 2026

Biocon stock declines after FDA inspection issuesBiocon's stock declined 1% after the US FDA raised five issues at its Bengaluru facility during an inspection. The company asserts these are procedural and poses no risk to data integrity, while also announcing Health Canada approvals for two denosumab biosimilars.Medium

March 2026

Stocks to watch as earnings surprise traders todayIndia's equity markets may see volatility today as earnings updates and corporate moves attract trader attention. Key stocks include Jio Financial Services, Waaree Renewable Technologies, and Biocon, with a focus on company-specific catalysts.Medium

February 2026

S&P Global raises Biocon Biologics’ credit rating to BB+S&P Global Ratings upgraded Biocon Biologics’ credit rating to BB+ from BB, citing a stable outlook. The upgrade follows a US$460 million equity issuance to settle US$1 billion in preference shares, improving the company's capital structure and credit strength.Medium

December 2025

Biocon Q2 profit surges on Equillium stake saleBiocon Ltd reported a five-fold increase in Q2 profit to ₹3.55 billion, driven by a one-off gain of ₹1.89 billion from the Equillium stake sale. This surge is likely to positively impact investor sentiment.High Biocon acquires shares in Biocon Biologics for $1.2 billionHigh Viatris signs agreements with Biocon on $815m stake saleHigh Biocon fully integrates Biocon Biologics as subsidiaryMedium Biocon to merge with Biocon Biologics for $5.5 billionHigh

November 2025

Biocon considers merger or IPO for Biocon BiologicsHigh Biocon explores $4.5 billion merger with Biocon BiologicsHigh

About Biocon Limited

exchange masters as of 18 Sept 2026 · classification by BSE
Company
Biocon Limited
Exchange
NSE · BSE 532523, group A
Listed on NSE
7 Apr 2004
Classification
Healthcare › Pharmaceuticals & Biotechnology › Pharmaceuticals
Index
BSE 200
Face value
₹5 a share
ISIN
INE376G01013
Sessions on record
272
Price source
NSE UDiFF bhavcopy · end of day · delayed
Filings
NSE and BSE public disclosures · results, shareholding and corporate actions as filed
Computed
1 Oct, 10:08 pm IST
Bulletins
24 · written by the desk · not a recommendation

OI Charts is not a SEBI-registered investment adviser or research analyst. Prices, open interest, filings and the desk read are exchange data and arithmetic on it, not a basis for any investment decision.